SRL
CRDL

Scientech Research LLC’s Cardiol Therapeutics CRDL Stock Holding History

Scientech Research LLC’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,178
Closed -$20.5K – 302
2026
Q1 		$20.5K Buy
+15,178
New +$15.6K 0.02% 435

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Scientech Research LLC's CRDL Position: Q2 2026 in Review

Scientech Research LLC sold out of Cardiol Therapeutics (CRDL) in Q2 2026, closing a stake of 15,178 shares — an estimated $20.5K sold.

Scientech Research LLC first reported a position in CRDL in Q1 2026 and held it in 1 quarter. The position peaked at $20.5K in Q1 2026. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Scientech Research LLC reported no remaining Cardiol Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Scientech Research LLC sold 15,178 Cardiol Therapeutics shares in Q2 2026, an estimated $20.5K.
  • Scientech Research LLC first reported a position in Cardiol Therapeutics in Q1 2026 and held it in 1 quarter.
  • Scientech Research LLC's Cardiol Therapeutics position peaked at $20.5K in Q1 2026.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.